Journal
IMMUNITY
Volume 50, Issue 4, Pages 1007-1023Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2019.03.026
Keywords
-
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan
- Astellas Foundation for Research on Metabolic Disorders
- Kishimoto Foundation
Ask authors/readers for more resources
Interleukin-6 (IL-6) is a pleiotropic cytokine with roles in immunity, tissue regeneration, and metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue injury, but excessive synthesis of IL-6 and dysregulation of IL-6 receptor signaling is involved in disease pathology. Therapeutic agents targeting the IL-6 axis are effective in rheumatoid arthritis, and applications are being extended to other settings of acute and chronic inflammation. Recent studies reveal that selective blockade of different modes of IL-6 receptor signaling has different outcomes on disease pathology, suggesting novel strategies for therapeutic intervention. However, some inflammatory diseases do not seem to respond to IL-6 blockade. Here, we review the current state of IL-6-targeting approaches in the clinic and discuss how to apply the growing understanding of the immunobiology of IL-6 to clinical decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available